J. Machiels Et Al. , "Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)," ESMO Immuno Oncology Congress , vol.28, Geneva, Switzerland, 2017
Machiels, J. Et Al. 2017. Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). ESMO Immuno Oncology Congress , (Geneva, Switzerland).
Machiels, J., Yen, C., Licitra, L., Rischin, D., Waldron, J., Burtness, B., ... Gregoire, V.(2017). Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) . ESMO Immuno Oncology Congress, Geneva, Switzerland
Machiels, J-P. Et Al. "Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)," ESMO Immuno Oncology Congress, Geneva, Switzerland, 2017
Machiels, J-P. Et Al. "Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)." ESMO Immuno Oncology Congress , Geneva, Switzerland, 2017
Machiels, J. Et Al. (2017) . "Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)." ESMO Immuno Oncology Congress , Geneva, Switzerland.
@conferencepaper{conferencepaper, author={J-P. Machiels Et Al. }, title={Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)}, congress name={ESMO Immuno Oncology Congress}, city={Geneva}, country={Switzerland}, year={2017}}